Agents in development for the treatment of diabetic nephropathy.

about

A novel improved therapy strategy for diabetic nephropathy: targeting AGEs.Dual therapy of vildagliptin and telmisartan on diabetic nephropathy in experimentally induced type 2 diabetes mellitus rats.

P2860

Q37986418-EBC0D9F4-10DA-4A2A-B4A8-4D55CE4D9AC2 Q51344978-6CC3DAA5-6517-49DA-8BFE-ADA67F14BF68

P2860

Agents in development for the treatment of diabetic nephropathy.

Item

http://www.wikidata.org/entity/Q36099419

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

2005年论文

@zh

2005年论文

@zh-cn

name

Agents in development for the treatment of diabetic nephropathy.

@ast

Agents in development for the treatment of diabetic nephropathy.

@en

type

Item

label

Agents in development for the treatment of diabetic nephropathy.

@ast

Agents in development for the treatment of diabetic nephropathy.

@en

prefLabel

Agents in development for the treatment of diabetic nephropathy.

@ast

Agents in development for the treatment of diabetic nephropathy.

@en

P1476

Agents in development for the treatment of diabetic nephropathy.

@en

P2093

Josephine M Forbes

http://www.w3.org/2001/XMLSchema#string

Kei Fukami

http://www.w3.org/2001/XMLSchema#string

Mark E Cooper

http://www.w3.org/2001/XMLSchema#string

P2860

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

Biochemistry and molecular cell biology of diabetic complications

Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: results from an international comparative study

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

Therapeutic potential of breakers of advanced glycation end product-protein crosslinks

Transforming growth factor beta in tissue fibrosis

P304

279-294

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.14.3.279

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2005-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

7904240

http://www.w3.org/2001/XMLSchema#string

P698

15833059

http://www.w3.org/2001/XMLSchema#string

Agents in development for the treatment of diabetic nephropathy.

about

P2860

P2860

Agents in development for the treatment of diabetic nephropathy.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698